Table 2 details of the products identified by the conditions treated (search conducted in February 2007).
From: Internet treatment of sexually transmitted infections – a public health hazard?
Chlamydia | Genital herpes | Genital warts | Gonorrhoea | |
|---|---|---|---|---|
Number of products | 5 | 39 | 29 | 4 |
Treatment recommended by UK treatment guidelines [11–15] | 3† | 0 | 4 | 3† |
Number of companies | 4 | 20‡ | 25‡ | 3 |
Country (shipping from) | ||||
China | - | 1 (3%) | 1 (3%) | - |
EU (unspecified) | - | 2 (5%) | 1 (3%) | - |
India | - | 1 (3%) | - | - |
New Zealand | 1 (20%) | 1 (3%) | 1 (3%) | - |
UK | 3 (60%) | 3 (8%) | 4 (14%) | 3 (75%) |
US | 1 (20%) | 29 (74%) | 16 (55%) | 1 (25%) |
Not specified | - | 2 (5%) | 6 (21%) | - |
Average (range) package cost§ | 58.28 (19.95–87.89) | 44.84 (14.95–290) | 56.99 (15.95–229) | 73.22 (39–107.42) |
Side effects reported* | 2 (40%) | 6 (15%) | 7 (24%) | 2 (50%) |
Contraindications reported* | 2 (40%) | 6 (15%) | 9 (31%) | 2 (50%) |
Interactions reported* | 2 (40)% | 2 (5%) | 1 (3%) | 2 (50%) |
Consultation offered* | 3 (60%) | 13 (33%) | 6 (21%) | 3 (75%) |
Recommended medical advice* | 3 (60%) | 7 (18%) | 5 (17%) | 3 (75%) |
Partner treatment* | 1 (20%) | - | 2 (7%) | 1 (25%) |
Prevention advice* | 2 (40%) | 2 (5%) | 4 (14%) | 2 (50%) |
Claims of effectiveness* | 3 (60%) | 24 (62%) | 9 (31%) | 2 (50%) |